Organon & Co. (LON:0A9W)

Market Cap	2.59B +4.8%
Revenue (ttm)	4.67B -2.1%
Net Income	186.30M -67.2%
EPS	0.71 -67.2%
Shares Out	n/a
PE Ratio	13.89
Forward PE	3.93
Dividend	0.06 (0.45%)
Ex-Dividend Date	May 11, 2026

Volume	806
Average Volume	41,100
Open	13.29
Previous Close	13.32
Day's Range	13.28 - 13.35
52-Week Range	5.71 - 13.42
Beta	1.55
RSI	79.22
Earnings Date	Apr 30, 2026

About Organon & Co.

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote develo...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 10,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A9W

Financial Performance

In 2025, Organon & Co.'s revenue was $6.22 billion, a decrease of -2.92% compared to the previous year's $6.40 billion. Earnings were $187.00 million, a decrease of -78.36%.

Financial numbers in USD